专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070027184A1 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease 审中-公开
标题翻译：多环磺酰胺化合物作为组蛋白脱乙酰酶的抑制剂用于治疗疾病
公开(公告)号：US20070027184A1
公开(公告)日：2007-02-01
申请号：US11496784
申请日：2006-07-27
申请人： James Malecha , Stewart Noble , Brandon Wiley , Timothy Hoffman , Celine Bonnefous , Michael Sertic , Paul Wash , Nicholas Smith , Christian Hassig , Shawn Scranton , Joseph Payne , Jeffery Hager
发明人： James Malecha , Stewart Noble , Brandon Wiley , Timothy Hoffman , Celine Bonnefous , Michael Sertic , Paul Wash , Nicholas Smith , Christian Hassig , Shawn Scranton , Joseph Payne , Jeffery Hager
IPC分类号： A61K31/47 , C07D215/12 , C07D319/14 , A61K31/36
CPC分类号： C07D405/12 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12
摘要： Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
摘要翻译：本文公开的是本文所述的式VII的磺酰胺化合物。公开了用于治疗疾病状态的方法和组合，包括但不限于癌症，自身免疫性疾病，组织损伤，中枢神经系统疾病，神经变性疾病，纤维化，骨病，聚谷氨酰胺 - 重复病症，贫血，地中海贫血，炎性病症，心血管疾病以及使用本发明化合物的血管发生在发病机理中起作用的病症。此外，还公开了调节组蛋白脱乙酰酶（HDAC）的活性的方法。

2. 发明申请

US20070135431A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE 审中-公开
标题翻译：用于治疗疾病的组织脱乙酰酶的抑制剂
公开(公告)号：US20070135431A1
公开(公告)日：2007-06-14
申请号：US11608726
申请日：2006-12-08
申请人： Nicholas Smith , Celine Bonnefous , Joseph Payne , Timothy Hoffman , Paul Wash , Christian Hassig , Shawn Scranton
发明人： Nicholas Smith , Celine Bonnefous , Joseph Payne , Timothy Hoffman , Paul Wash , Christian Hassig , Shawn Scranton
IPC分类号： A61K31/5377 , A61K31/454 , A61K31/4439 , C07D413/14 , C07D401/14
CPC分类号： C07D401/12 , C07C327/30 , C07D211/46 , C07D213/30 , C07D213/38 , C07D213/76 , C07D295/096 , C07D295/26 , C07D413/12
摘要： Disclosed herein are carbonyl compounds of having the structural formula: or a salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
摘要翻译：本文公开了具有以下结构式的羰基化合物：或其盐，酯或前药。公开了用于治疗疾病状态的方法和组合物，包括但不限于癌症，自身免疫疾病，组织损伤，中枢神经系统疾病，神经变性使用本发明的化合物，疾病，纤维化，骨病，聚谷氨酰胺重复病症，贫血，地热病，炎性病症，心血管病症和血管发生在发病机理中发挥作用的病症。此外，还公开了调节组蛋白脱乙酰酶（HDAC）的活性的方法。

3. 发明申请

US20070135438A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE 审中-公开
标题翻译：用于治疗疾病的组织脱乙酰酶的抑制剂
公开(公告)号：US20070135438A1
公开(公告)日：2007-06-14
申请号：US11608736
申请日：2006-12-08
申请人： Joseph Payne , Nicholas Smith , Shawn Scranton , Christian Hassig
发明人： Joseph Payne , Nicholas Smith , Shawn Scranton , Christian Hassig
IPC分类号： A61K31/53 , A61K31/4965 , C07D253/08 , A61K31/505
CPC分类号： C07D213/76 , C07D405/12
摘要： Disclosed herein are carbonyl compounds of having the structural formula: or a pharmaceutically acceptable salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
摘要翻译：本文公开了具有以下结构式的羰基化合物：或其药学上可接受的盐，酯或前药。公开了用于治疗疾病状态的方法和组合物，包括但不限于癌症，自身免疫疾病，组织损伤，中枢神经系统疾病使用本发明的化合物，神经变性疾病，纤维化，骨病，聚谷氨酰胺重复病症，贫血，地热病，炎性病症，心血管病症和血管生成在发病机理中发挥作用的病症。此外，还公开了调节组蛋白脱乙酰酶（HDAC）的活性的方法。

4. 发明申请

US20060189682A1 Water soluble prodrugs of COX-2 inhibitors 审中-公开
标题翻译： COX-2抑制剂的水溶性前药
公开(公告)号：US20060189682A1
公开(公告)日：2006-08-24
申请号：US11345694
申请日：2006-02-02
申请人： Joseph Payne , Steve Poon , Nicholas Smith , Nicholas Stock , Angela McGuire
发明人： Joseph Payne , Steve Poon , Nicholas Smith , Nicholas Stock , Angela McGuire
IPC分类号： A61K31/343 , C07D493/10
CPC分类号： C07D493/10
摘要： Disclosed are water soluble compounds which are useful as prodrugs of COX-2 inhibitors, and pharmaceutical compositions comprising them.
摘要翻译：公开了可用作COX-2抑制剂的前药的水溶性化合物和包含它们的药物组合物。

5. 发明申请

US20060216491A1 Bonded structures formed form multicomponent fibers having elastomeric components for use as ink reservoirs 审中-公开
标题翻译：由多组分纤维形成的粘合结构具有用作墨水储存器的弹性体组分
公开(公告)号：US20060216491A1
公开(公告)日：2006-09-28
申请号：US11378065
申请日：2006-03-17
申请人： Bennett Ward , Jian Xiang , Andreas Schneekloth , Jackie Payne , Joseph Payne
发明人： Bennett Ward , Jian Xiang , Andreas Schneekloth , Jackie Payne , Joseph Payne
IPC分类号： D04H13/00
CPC分类号： B41J2/17513 , D04H1/4358 , D04H1/541 , D04H1/56 , D04H1/76 , D04H3/077 , D04H3/16 , Y10T428/249924
摘要： A bonded fiber ink reservoir, an ink jet printer cartridge containing a bonded fiber reservoir, and a ink jet printer using an ink jet cartridge containing a bonded fiber reservoir are disclosed. The bonded fiber reservoir may comprise a three dimensional bonded fiber structure, wherein the three dimensional bonded fiber structure is comprised of a plurality of fibers bonded to each other at spaced apart points of contact, at least a portion of the fibers being multicomponent fibers having at least one elastomeric fiber component.
摘要翻译：公开了一种粘合纤维油墨储存器，包含粘合纤维储存器的喷墨打印机墨盒和使用包含粘合纤维储器的喷墨墨盒的喷墨打印机。结合纤维储存器可以包括三维结合的纤维结构，其中三维结合的纤维结构由在间隔开的接触点处彼此结合的多根纤维组成，至少一部分纤维是多组分纤维，至少一种弹性纤维组分。

6. 发明申请

US20110257137A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE 审中-公开
标题翻译：组胺类受体的治疗疾病的杂环抑制剂
公开(公告)号：US20110257137A1
公开(公告)日：2011-10-20
申请号：US13044906
申请日：2011-03-10
申请人： Allen Borchardt , Robert Davis , Clay Beauregard , Daniel Becker , Daniel Gamache , Stewart A. Noble , Mark Hellberg , Peter Klimko , Zhihai Qiu , Joseph Payne , John Yanni
发明人： Allen Borchardt , Robert Davis , Clay Beauregard , Daniel Becker , Daniel Gamache , Stewart A. Noble , Mark Hellberg , Peter Klimko , Zhihai Qiu , Joseph Payne , John Yanni
IPC分类号： A61K31/56 , C07D498/04 , A61K31/4985 , A61K31/519 , A61K31/551 , A61K31/5377 , A61K31/496 , A61P29/00 , A61P37/08 , A61P11/06 , A61P27/02 , A61P11/00 , A61P17/00 , A61P17/04 , C07D487/04
CPC分类号： C07D471/04 , C07D487/04 , C07D498/04 , C07D519/00
摘要： The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
摘要翻译：本发明涉及可用作H1R和/或H4R抑制剂用于治疗或预防炎性，自身免疫性，过敏性和眼部疾病的化合物和方法。

7. 发明申请

US20050072737A1 Polymeric fiber rods for separation applications 失效
标题翻译：用于分离应用的聚合纤维棒
公开(公告)号：US20050072737A1
公开(公告)日：2005-04-07
申请号：US10921720
申请日：2004-08-19
申请人： Bennett Ward , Samila Mihindukulasuriya , David Harris , Joseph Payne
发明人： Bennett Ward , Samila Mihindukulasuriya , David Harris , Joseph Payne
IPC分类号： B01D15/08 , B01J20/282 , B01J20/285 , D01F20060101
CPC分类号： B01J20/282 , B01J20/28023 , B01J20/28028 , B01J20/285 , B01J2220/52 , B01J2220/54 , B01J2220/58
摘要： A separation element is provided for use in a chromatographic analysis system for the separation of a mixture using a stationary phase and a mobile phase. The separation element comprises a fluid transmissive fiber rod comprising a plurality of fibers entangled to provide a tortuous path through which a mobile phase may flow as part of a separation process. The plurality of fibers provides a stationary phase for the separation process.
摘要翻译：提供分离元件用于色谱分析系统，用于使用固定相和流动相分离混合物。分离元件包括流体传输纤维杆，其包括多个纤维缠结以提供曲折路径，流动相可以作为分离过程的一部分流过。多个纤维提供用于分离过程的固定相。

8. 发明授权

US08836033B1 Method and apparatus for removing metallic nanotubes without transferring carbon nanotubes from one substrate to another substrate 有权
标题翻译：用于去除金属纳米管而不将碳纳米管从一个基底转移到另一个基底的方法和装置
公开(公告)号：US08836033B1
公开(公告)日：2014-09-16
申请号：US13357796
申请日：2012-01-25
申请人： Silai Krishnaswamy , Joseph Payne , Jeffrey Hartman
发明人： Silai Krishnaswamy , Joseph Payne , Jeffrey Hartman
IPC分类号： G02B5/30
CPC分类号： B82Y30/00 , B82Y40/00
摘要： Embodiments of a method and apparatus for removing metallic nanotubes without transferring CNTs from one substrate to another substrate provide two methods of transferring a thin layer of crystalline ST-cut quartz wafer to the surface of a carrier silicon wafer for subsequent CNT growth, without resorting to CNT transfer. In other words, embodiments of a method and apparatus allow CNTs to be grown on the same substrate that metallic nanotube removal is performed, therefore eliminating the costly and messy step of transferring CNTs from one substrate to another. This is achieved through a residual thin layer of crystalline ST-cut quartz layer on a silicon wafer. The ST-cut quartz wafer promotes aligned growth of CNTs, while the underlying silicon wafer allows backgate burnout.
摘要翻译：用于去除金属纳米管而不将CNT从一个衬底转移到另一个衬底的方法和设备的实施例提供了将晶体ST切割石英晶片的薄层转移到载体硅晶片的表面以用于随后的CNT生长的两种方法，而不诉诸于 CNT转移。换句话说，方法和装置的实施例允许CNT在相同的衬底上生长金属纳米管去除，因此消除了将碳纳米管从一个衬底转移到另一个衬底的昂贵和混乱的步骤。这通过在硅晶片上的晶体ST切割石英层的残留薄层来实现。 ST切割的石英晶片促进CNT的对准生长，而下面的硅晶片允许背栅板烧尽。

9. 发明授权

US08242143B2 Thiazolyl mGluR5 antagonists and methods for their use 有权
标题翻译：噻唑基mGluR5拮抗剂及其使用方法
公开(公告)号：US08242143B2
公开(公告)日：2012-08-14
申请号：US13016304
申请日：2011-01-28
申请人： Nicholas D. Cosford , Thomas J. Seiders , Joseph Payne , Jeffrey R. Roppe , Dehua Huang , Nicholas D. Smith , Steve F. Poon , Chris King , Brian W. Eastman , Bowei Wang , Jeannie M. Arruda , Jean-Michel Vernier , Xiumin Zhao
发明人： Nicholas D. Cosford , Thomas J. Seiders , Joseph Payne , Jeffrey R. Roppe , Dehua Huang , Nicholas D. Smith , Steve F. Poon , Chris King , Brian W. Eastman , Bowei Wang , Jeannie M. Arruda , Jean-Michel Vernier , Xiumin Zhao
IPC分类号： A61P25/00 , A61K31/44 , C07D417/00
CPC分类号： C07D417/06 , C07D417/14 , C07D471/04
摘要： The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.
摘要翻译：由于在效力和/或药代动力学和/或选择性和/或体内受体占有性方面具有有利的性质，鉴定了具有药物性质特征的独特系列化合物。具体地说，通过亚乙炔基连接到吡啶环的3位或嘧啶环的5位上的1,3-噻唑-2-基环成员的选择，其中环被选定的取代基取代，得到具有优异药物性质的化合物。本发明包括这些杂环化合物的药学上可接受的盐形式，特别是氯化物盐和三氟乙酸盐。

10. 发明申请

US20090203903A1 Thiazolyl mglur5 antagonists and methods for their use 有权
标题翻译：噻唑基mglur5拮抗剂及其使用方法
公开(公告)号：US20090203903A1
公开(公告)日：2009-08-13
申请号：US11664902
申请日：2005-10-06
申请人： Nicholas D. Cosford , Thomas J. Seiders , Joseph Payne , Jeffrey R. Roppe , Dehua Huang , Nicholas D. Smith , Steve F. Poon , Chris King , Brian W. Eastman , Bowei Wang , Jeannie M. Arruda , Jean-Michel Vernier , Xiumin Zhao
发明人： Nicholas D. Cosford , Thomas J. Seiders , Joseph Payne , Jeffrey R. Roppe , Dehua Huang , Nicholas D. Smith , Steve F. Poon , Chris King , Brian W. Eastman , Bowei Wang , Jeannie M. Arruda , Jean-Michel Vernier , Xiumin Zhao
IPC分类号： C07D417/14 , C07D417/06
CPC分类号： C07D417/06 , C07D417/14 , C07D471/04
摘要： The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.
摘要翻译：由于在效力和/或药代动力学和/或选择性和/或体内受体占有性方面具有有利的性质，鉴定了具有药物性质特征的独特系列化合物。具体地说，通过亚乙炔基连接到吡啶环的3位或嘧啶环的5位上的1,3-噻唑-2-基环成员的选择，其中环被选定的取代基取代，得到具有优异药物性质的化合物。本发明包括这些杂环化合物的药学上可接受的盐形式，特别是氯化物盐和三氟乙酸盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式